• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of t-PA and of t-PA on the variant's anticoagulant activity.3K3A活化蛋白C变体对组织型纤溶酶原激活物（t-PA）血浆凝块溶解活性的影响以及t-PA对该变体抗凝活性的影响。
J Thromb Haemost. 2013 Nov;11(11):2059-62. doi: 10.1111/jth.12400.
2
3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase.3K3A 激活蛋白 C 变异体不干扰替奈普酶的血浆血栓溶解活性。
Stroke. 2020 Jul;51(7):2236-2239. doi: 10.1161/STROKEAHA.120.028793. Epub 2020 Jun 17.
3
Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity.抗凝活性降低的活化蛋白C突变体的物种依赖性神经保护作用。
J Neurochem. 2009 Apr;109(1):116-24. doi: 10.1111/j.1471-4159.2009.05921.x. Epub 2009 Jan 23.
4
In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.体外凝块溶解作为血栓对纤维蛋白溶解抵抗的潜在指标——在健康受试者中的研究及其与血液纤溶参数的相关性
Thromb Haemost. 1997 Apr;77(4):725-9.
5
Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.rt-PA del（K296-G302）的生化及生物学特性，一种对纤溶酶原激活物抑制剂-1具有抗性的重组人组织型纤溶酶原激活物缺失突变体
Blood. 1992 Jan 15;79(2):417-29.
6
Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator.重组葡萄球菌激酶与单链尿激酶型纤溶酶原激活剂组合的体外溶栓作用协同性。
Biochemistry (Mosc). 2003 Nov;68(11):1252-60. doi: 10.1023/b:biry.0000009141.17272.6c.
7
Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.在犬动静脉联合血栓形成模型中组织型纤溶酶原激活剂（t-PA）、单链尿激酶型纤溶酶原激活剂（u-PA）和K1K2Pu（一种t-PA/u-PA嵌合体）的溶栓特性比较
J Am Coll Cardiol. 1992 May;19(6):1350-9. doi: 10.1016/0735-1097(92)90344-m.
8
Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).添加不同浓度重组组织型纤溶酶原激活剂（Rt-PA）后新生儿和成人全血凝块的溶解情况。
Semin Thromb Hemost. 1998;24(6):599-604. doi: 10.1055/s-2007-996060.
9
Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy.血浆凝块溶解过程中纤维蛋白网络的重排及纤溶成分的空间分布。共聚焦显微镜研究。
J Biol Chem. 1996 Jan 26;271(4):2133-8. doi: 10.1074/jbc.271.4.2133.
10
Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system.在体外流动系统中使用纤溶酶或重组组织型纤溶酶原激活剂对初始和动态凝块溶解进行直接显微镜监测。
Thromb Res. 2014 May;133(5):908-13. doi: 10.1016/j.thromres.2014.02.008. Epub 2014 Feb 22.

引用本文的文献

1
Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic Transformation.使用PAR-1拮抗剂治疗中风以减少出血性转化。
Front Neurol. 2021 Mar 15;12:593582. doi: 10.3389/fneur.2021.593582. eCollection 2021.
2
3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase.3K3A 激活蛋白 C 变异体不干扰替奈普酶的血浆血栓溶解活性。
Stroke. 2020 Jul;51(7):2236-2239. doi: 10.1161/STROKEAHA.120.028793. Epub 2020 Jun 17.
3
Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research.急性缺血性卒中的I期和II期治疗：临床研究中当前所研究药物的最新进展
Biomed Res Int. 2017;2017:4863079. doi: 10.1155/2017/4863079. Epub 2017 Feb 14.
4
Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.通过超因子Va和因子VIIa联合使用改善血友病伴抑制剂患者的凝血和止血功能。
Thromb Haemost. 2016 Mar;115(3):551-61. doi: 10.1160/TH15-07-0525. Epub 2015 Oct 15.
5
Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers.3K3A-APC在健康成年志愿者中的1期安全性、耐受性和药代动力学
Curr Pharm Des. 2013;19(42):7479-85. doi: 10.2174/1381612819666131230131454.

本文引用的文献

1
Intravenous recombinant tissue-type plasminogen activator in the extended time window and the US Food and Drug Administration: confused about the time.延长时间窗内静脉注射重组组织型纤溶酶原激活剂与美国食品药品监督管理局：对时间感到困惑
Stroke. 2012 Sep;43(9):2517-9. doi: 10.1161/STROKEAHA.112.670554. Epub 2012 Aug 21.
2
An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.一种抗凝活性降低的活化蛋白 C 类似物延长了组织型纤溶酶原激活物治疗缺血性脑卒中的治疗窗口。
Stroke. 2012 Sep;43(9):2444-9. doi: 10.1161/STROKEAHA.112.658997. Epub 2012 Jul 17.
3
Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke.用于缺血性脑卒中的新型改良活化蛋白 C 3K3A-APC 的临床前安全性和药代动力学特征。
Curr Pharm Des. 2012;18(27):4215-22. doi: 10.2174/138161212802430413.
4
Cytoprotective protein C pathways and implications for stroke and neurological disorders.细胞保护蛋白 C 途径及其在中风和神经紊乱中的意义。
Trends Neurosci. 2011 Apr;34(4):198-209. doi: 10.1016/j.tins.2011.01.005. Epub 2011 Feb 25.
5
Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity.抗凝活性降低的活化蛋白C突变体的神经保护活性
Eur J Neurosci. 2009 Mar;29(6):1119-30. doi: 10.1111/j.1460-9568.2009.06664.x.
6
Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions.具有最小抗凝活性、正常细胞保护活性且保留凝血酶激活的纤维蛋白溶解抑制剂依赖性细胞保护功能的活化蛋白C突变体。
J Biol Chem. 2007 Nov 9;282(45):33022-33. doi: 10.1074/jbc.M705824200. Epub 2007 Sep 14.
7
The cytoprotective protein C pathway.细胞保护蛋白C途径。
Blood. 2007 Apr 15;109(8):3161-72. doi: 10.1182/blood-2006-09-003004. Epub 2006 Nov 16.
8
Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage.活化蛋白C可抑制组织型纤溶酶原激活剂诱导的脑出血。
Nat Med. 2006 Nov;12(11):1278-85. doi: 10.1038/nm1498. Epub 2006 Oct 29.
9
Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis.凝血酶激活的纤维蛋白溶解抑制剂对纤维蛋白溶解的调节作用，该抑制剂是一种不稳定的羧肽酶B，它将凝血和纤维蛋白溶解途径联系起来。
Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2445-53. doi: 10.1161/01.ATV.0000244680.14653.9a. Epub 2006 Sep 7.
10
Alteplase for acute stroke revisited: the first 10 years.急性卒中使用阿替普酶再审视：首个十年
Lancet Neurol. 2006 Sep;5(9):722-4. doi: 10.1016/S1474-4422(06)70530-0.

Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of t-PA and of t-PA on the variant's anticoagulant activity.

作者信息

Mosnier L O, Fernández J A, Davis T P, Zlokovic B V, Griffin J H

机构信息

Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA.

出版信息

J Thromb Haemost. 2013 Nov;11(11):2059-62. doi: 10.1111/jth.12400.

DOI:10.1111/jth.12400
PMID:24034518
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3850769/
Abstract
摘要